Evidence map›Paper›PMID 26937040›Full record

ArticleJournal of virology2016

Effects of Fecal Microbial Transplantation on Microbiome and Immunity in Simian Immunodeficiency Virus-Infected Macaques.

Tiffany Hensley-McBain, Alexander S Zevin, Jennifer Manuzak, Elise Smith, Jillian Gile, Charlene Miller, Brian Agricola, Michael Katze, R Keith Reeves, Colleen S Kraft and 2 more

Open access · bronzeAbstract readEvaluation Study
In one paragraph

Article in Journal of virology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
65citing papers in PubMed, 2 pooled it
8.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

65 citing papers in PubMed, 2 syntheses or guidelines pooled it, 96 citations in OpenAlex.

  1. The Hitchhiker Guide to CD4Frontiers in immunology · 2021
    Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. Review
  20. Review

5 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Tiffany Hensley-McBainDepartment of Pharmaceutics, University of Washington, Seattle, Washington, USA.
Alexander S ZevinDepartment of Pharmaceutics, University of Washington, Seattle, Washington, USA.
Jennifer ManuzakDepartment of Pharmaceutics, University of Washington, Seattle, Washington, USA.
Elise SmithWashington National Primate Research Center (WaNPRC), University of Washington, Seattle, Washington, USA.
Jillian GileDepartment of Pharmaceutics, University of Washington, Seattle, Washington, USA.
Charlene MillerDepartment of Pharmaceutics, University of Washington, Seattle, Washington, USA.
Brian AgricolaWashington National Primate Research Center (WaNPRC), University of Washington, Seattle, Washington, USA.
Michael KatzeWashington National Primate Research Center (WaNPRC), University of Washington, Seattle, Washington, USA.
R Keith ReevesCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.
Colleen S KraftDepartment of Pathology and Laboratory Medicine, Emory University Hospital, Atlanta, Georgia, USA.
Stanley LangevinWashington National Primate Research Center (WaNPRC), University of Washington, Seattle, Washington, USA.
Nichole R KlattDepartment of Pharmaceutics, University of Washington, Seattle, Washington, USA klattnr@uw.edu.
University of Washington · USBeth Israel Deaconess Medical Center · USEmory University Hospital · US

Funding

Washington National Primate Research CenterP51OD010425 · OD · UNIVERSITY OF WASHINGTON · PI Mari Ostendorf · 2012 to 2026
$201.8M
National Institute on Aging (NIA) ColonyP51OD011107 · OD · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Simon J. Atkinson · 2012 to 2026
$191.5M
Persistent modulation of microbiota to enhance HIV vaccinationR01AI120712 · NIAID · UNIVERSITY OF WASHINGTON · PI KLATT, NICHOLE ROSE · 2015 to 2019
$4.0M
Mucosal Immune Dysfunction after SIV InfectionK22AI098440 · NIAID · UNIVERSITY OF WASHINGTON · PI KLATT, NICHOLE ROSE · 2013 to 2014
$270k
NIAID NIH HHS K22 AI098440NIAID NIH HHS R01 AI120712NIH HHS P51 OD010425NIH HHS P51 OD011107
6 · The paper itself

Abstract

unlabelledAn altered intestinal microbiome during chronic human immunodeficiency virus (HIV) infection is associated with mucosal dysfunction, inflammation, and disease progression. We performed a preclinical evaluation of the safety and efficacy of fecal microbiota transplantation (FMT) as a potential therapeutic in HIV-infected individuals. Antiretroviral-treated, chronically simian immunodeficiency virus (SIV)-infected rhesus macaques received antibiotics followed by FMT. The greatest microbiota shift was observed after antibiotic treatment. The bacterial community composition at 2 weeks post-FMT resembled the pre-FMT community structure, although differences in the abundances of minor bacterial populations remained. Immunologically, we observed significant increases in the number of peripheral Th17 and Th22 cells and reduced CD4(+) T cell activation in gastrointestinal tissues post-FMT. Importantly, the transplant was well tolerated with no negative clinical side effects. Although this pilot study did not control for the differential contributions of antibiotic treatment and FMT to the observed results, the data suggest that FMT may have beneficial effects that should be further evaluated in larger studies. IMPORTANCE: Due to the immunodeficiency and chronic inflammation that occurs during HIV infection, determination of the safety of FMT is crucial to prevent deleterious consequences if it is to be used as a treatment in the future. Here we used the macaque model of HIV infection and performed FMT on six chronically SIV-infected rhesus macaques on antiretroviral treatment. In addition to providing a preclinical demonstration of the safety of FMT in primates infected with a lentivirus, this study provided a unique opportunity to examine the relationships between alterations to the microbiome and immunological parameters. In this study, we found increased numbers of Th17 and Th22 cells as well as decreased activation of CD4(+) T cells post-FMT, and these changes correlated most strongly across all sampling time points with lower-abundance taxonomic groups and other taxonomic groups in the colon. Overall, these data provide evidence that changes in the microbiome, particularly in terms of diversity and changes in minor populations, can enhance immunity and do not have adverse consequences.

Indexed as

Fecal Microbiota TransplantationGastrointestinal MicrobiomeAnimalsAnti-Bacterial AgentsCD4-Positive T-LymphocytesColonDisease Models, AnimalGenes, rRNAHIV InfectionsHumansIntestinesLymphocyte ActivationMacaca mulattaPilot ProjectsRNA, Ribosomal, 16SSimian Acquired Immunodeficiency SyndromeAnti-Bacterial AgentsRNA, Ribosomal, 16S

Identifiers

PMID26937040
PMCPMC4859719
OpenAlexW2344521110

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.